RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cost-effectiveness of nivolumab for the adjuvant treatment of muscle-invasive urothelial carcinoma patients with high risk of recurrence and tumor cell Pd-L1 expression ≥ 1% in Sweden
Kamgar, F., Johannesen, K., Thybo, S., Teitsson, S., & Brodtkorb, T. (2022). Cost-effectiveness of nivolumab for the adjuvant treatment of muscle-invasive urothelial carcinoma patients with high risk of recurrence and tumor cell Pd-L1 expression ≥ 1% in Sweden. Value in Health, 25(12), S146. Article EE462. https://doi.org/10.1016/j.jval.2022.09.707
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.